These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3680308)

  • 21. Induction of skin resistance to vaccinia virus in rabbits by vaccinia-soluble early antigens.
    Ueda Y; Tagaya I
    J Exp Med; 1973 Nov; 138(5):1033-43. PubMed ID: 4744920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of human immunological responses to vaccinia virus.
    Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
    Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein.
    Earl PL; Americo JL; Moss B
    J Virol; 2003 Oct; 77(19):10684-8. PubMed ID: 12970455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccinia virus strain differences. I. Neutralization of vaccinia virus strains by homologous and heterologous antisera.
    Dunlap RC; Barker LF
    Arch Gesamte Virusforsch; 1973; 42(2):107-16. PubMed ID: 4126981
    [No Abstract]   [Full Text] [Related]  

  • 25. Study of the kinetics of neutralization of the vaccina virus by means of titration of the homologous antiserum.
    Rapicetta M; Mancini G; Santoro R
    Boll Ist Sieroter Milan; 1973; 52(4):315-20. PubMed ID: 4798236
    [No Abstract]   [Full Text] [Related]  

  • 26. Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein.
    Isaacs SN; Argyropoulos E; Sfyroera G; Mohammad S; Lambris JD
    J Virol; 2003 Aug; 77(15):8256-62. PubMed ID: 12857894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation of a respiratory syncytial virus human reference serum for use in the quantitation of neutralization antibody.
    Yang DP; Zielinska E; Quiroz J; Madore D; Rappaport R
    Biologicals; 2007 Jun; 35(3):183-7. PubMed ID: 17241789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune response to vaccinia virus and recombinant virus products in dogs.
    Appel MJ; Paoletti E
    Am J Vet Res; 1988 Nov; 49(11):1932-4. PubMed ID: 2977718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine.
    McClain DJ; Summers PL; Harrison SA; Schmaljohn AL; Schmaljohn CS
    J Med Virol; 2000 Jan; 60(1):77-85. PubMed ID: 10568767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization Assay for Chikungunya Virus Infection: Plaque Reduction Neutralization Test.
    Azami NA; Moi ML; Takasaki T
    Methods Mol Biol; 2016; 1426():273-82. PubMed ID: 27233280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural analysis and immunogenicity of recombinant major envelope protein (rA27L) of buffalopox virus, a zoonotic Indian vaccinia-like virus.
    Kumar A; Yogisharadhya R; Bhanuprakash V; Venkatesan G; Shivachandra SB
    Vaccine; 2015 Oct; 33(41):5396-5405. PubMed ID: 26319070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunogenicity of a recombinant strain of vaccinia virus, expressing a Venezuelan equine encephalomyelitis virus structural protein gene in peroral immunization].
    Sviatchenko VA; Kiselev NN; Ryzhikov AB; Bulychev LE; Mikriukova TP; Netesov SV
    Vopr Virusol; 2000; 45(6):38-41. PubMed ID: 11200645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expeditious neutralization assay for human metapneumovirus based on a recombinant virus expressing Renilla luciferase.
    Zhou M; Kitagawa Y; Yamaguchi M; Uchiyama C; Itoh M; Gotoh B
    J Clin Virol; 2013 Jan; 56(1):31-6. PubMed ID: 23084005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immune response to infection with vaccinia virus in mice. I. Infection and the production of antibody neutralizing cell-associated and cell-free virus.
    Hutt LM
    J Hyg (Lond); 1975 Jun; 74(3):301-14. PubMed ID: 168248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple sclerosis and elevation of cerebrospinal fluid vaccinia virus antibody.
    Thompson JA; Bray PF; Glasgow LA
    Neurology; 1975 Jan; 25(1):94-6. PubMed ID: 1167412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus.
    Berinstein A; Tami C; Taboga O; Smitsaart E; Carrillo E
    Vaccine; 2000 Apr; 18(21):2231-8. PubMed ID: 10717342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A refined complement-enhanced neutralization test for detecting antibodies to Junin virus.
    Barrera Oro JG; McKee KT; Spisso J; Mahlandt BG; Maiztegui JI
    J Virol Methods; 1990 Jul; 29(1):71-80. PubMed ID: 2170437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Approach to the development of an actovaccine using vaccinia virus as a model].
    Chimishkian KL; Svet-Moldavskiĭ GIa
    Vopr Virusol; 1975; (3):273-8. PubMed ID: 1162946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.